Next-generation sequencing
Deepen understanding, optimize outcomes
Molecular testing is recommended for individuals with advanced lung cancer to identify genetic abnormalities that may predict response to targeted therapies. Optimized therapy selection in patients with lung cancer is critical to achieving the best outcomes.
Next-generation sequencing Test menu
Next-generation sequencing panels
Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information also can be useful in prognosis.
Our lung cancer-specific next-generation sequencing panel includes only clinically relevant markers, allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of formalin-fixed, paraffin-embedded (FFPE) tissue and accepting cytology, which allows more patients to receive results.
Key testing
- MCLNG | MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
- Provides prognostic and therapeutic answers based on assessment of 12 genes for mutations and seven genes for rearrangements.
- Requires smaller amounts of tissue for hard-to-acquire specimens.
- Provides microsatellite instability (MSI) status for immunotherapy guidance.
- MCLNM | MayoComplete Lung Cancer Mutations, Next-Generation Sequencing, Tumor
- Analyzes mutations for 12 genes.
- MCLNR | MayoComplete Lung Rearrangements, Rapid, Tumor
- Analyzes rearrangements for 7 genes.
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.
Resistance mutation testing
Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.
- T790M | Cell-Free DNA EGFR T790M Mutation Analysis, Blood
- Determines EGFR T790M mutation status in blood specimens as an alternative to invasive tissue biopsies.
- Identifies patients with non-small cell lung cancer who harbor a T790M mutation and may benefit from specific epidermal growth factor receptor (EGFR)-targeted therapies.